Louis Calméjane

Jul 20, 2023 | onlinelibrary.wiley.com | Louis Calméjane |David Laharie |Julien Kirchgesner |Mathieu Uzzan

Infliximab or ciclosporin: Considerations for the choice of treatment As seen previously, infliximab and ciclosporin have both proved effective for the management of ASUC. The selection of second-line therapies can be influenced by clinicians' habits, patients' features, safety, or efficacy concerns. While CNIs can induce a swift response, infliximab is usually favored due to fewer monitoring and better safety profile.